EDAP TMS S.A. (FOCL)
Makes ultrasound devices to treat prostate cancer and kidney stones non-invasively
$6.06-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+366.2%
The outlook
FOCL is trading near its 52-week highs with analyst consensus firmly in buy territory. The stock sits above both its 50- and 200-day moving averages, and the average analyst price target sits roughly 40% above the current price. Coverage is moderate with five analysts tracking the name.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range98% of the way from its 52-week low to high
Price targetAvg target +40% vs current price
Analyst price target
~12-month · 5 analysts$8.50average target+40.3% vs now
Now $6.06
Low $3.00High $15.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$227.1M
52-wk high
$6.18
52-wk low
$1.21
50-day avg
$4.96
200-day avg
$3.73
Trailing P/E
—